Biomarkers of apoptosis

British Journal of Cancer

Volumn 99, Issue 6, 2008, Pages 841-846

  Ward, T H ^a   Cummings, J ^a   Dean, E ^a   Greystoke, A ^a   Hou, J M ^a   Backen, A ^b   Ranson, M ^c   Dive, C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Biomarkers; Circulating tumour cells; Cytokeratins; Multiplex ELISA; Nucleosomal DNA

Indexed keywords

BIOLOGICAL MARKER; CASPASE 2; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; CYTOKERATIN; DNA; FAS ANTIGEN; FAS LIGAND; HISTONE H2AX; PHOSPHATIDYLSERINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; NUCLEOSOME; PRIORITY JOURNAL; PROTEOMICS; SHORT SURVEY; TUMOR CELL;

ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 51449109585     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604519     Document Type: Short Survey

References (32)

1. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC, Linder S (2003) A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8: 263-268
2. Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2: 689- 700
3. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791
4. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95: 42-48
5. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C (2008) Biomarker method validation in anticancer drug development. Br J Pharmacol 153: 646-656
6. Cummings J, Ward TH, Ranson M, Dive C (2004) Apoptosis pathway-targeted drugs - from the bench to the clinic. Biochim Biophys Acta 1705: 53-66
7. Elshal MF, McCoy JP (2006) Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38: 317-323
8. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH (2006) Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 9: 1-17
9. Hidalgo M (2004) New target, new drug, old paradigm. J Clin Oncol 22: 2270-2272
10. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D (2006) Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann NY Acad Sci 1075: 244-257
11. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288
12. Kattan MW (2003) Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95: 634-635
13. Kersten B, Wanker EE, Hoheisel JD, Angenendt P (2005) Multiplex approaches in protein microarray technology. Expert Rev Proteomics 2: 499-510
14. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715
15. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756
16. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'Hara SM, Russell T, Terstappen LW (2004) Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 62: 46-53
17. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, Fourcroy JL, Dixit R, Pandite L, Pietrusko RG, Soares HD, Quarmby V, Vesterqvist OL, Potter DM, Witliff JL, Fritche HA, O'Leary T, Perlee L, Kadam S, Wagner JA (2005) Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 22: 499-511
18. Ling MM, Ricks C, Lea P (2007) Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn 7: 87-98
19. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856
20. Makin G, Dive C (2001) Apoptosis and cancer chemotherapy. Trends Cell Biol 11: S22-S26
21. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, Nieva J, Kuhn P (2007) Case study of the morphologic variation of circulating tumor cells. Hum Pathol 38: 514-519
22. Mehes G, Witt A, Kubista E, Ambros PF (2001) Circulating breast cancer cells are frequently apoptotic. Am J Pathol 159: 17-20
23. Nielsen UB, Geierstanger BH (2004) Multiplexed sandwich assays in microarray format. J Immunol Methods 290: 107-120
24. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13: 3198-3206
25. Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96: 213 -268
26. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11: 3974-3986
27. Taatjes DJ, Sobel BE, Budd RC (2008) Morphological and cytochemical determination of cell death by apoptosis. Histochem Cell Biol 129: 33-43
28. Taylor K, Micha D, Ranson M, Dive C (2006) Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opin Investig Drugs 15: 669-690
29. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M (2007) The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56: 399-404
30. Voorzanger-Rousselot N, Garnero P (2007) Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev 33: 230-283
31. Wagner JA (2002) Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18: 41-46
32. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64